"Interojo: Expanding Growth Potential... Increasing Valuation Appeal" [Click e-Stock]

On June 10, NH Investment & Securities evaluated Interojo, noting that the company is expected to achieve sales growth and expand its global distribution channels based on its recent FDA 510(k) approval from the U.S. Food and Drug Administration (FDA).

Researcher Sim Eui-seop at NH Investment & Securities stated, "The company recently received FDA 510(k) approval for its own silicone hydrogel (Si-Hy) contact lenses. Following the final approval, Interojo is also pursuing additional approvals for daily disposable and colored lenses, in addition to its monthly clear lenses, and expects to obtain these within the year." He added, "By expanding its certified product lineup, the company is expected to increase its supply volume. Interojo is actively restructuring contracts with overseas partners and broadening its distribution channels in various countries, implementing multifaceted strategies for sales growth."

Interojo has developed and proactively launched silicone hydrogel lenses with maximized oxygen permeability. In addition to clear lenses, the company also offers a lineup of colored lenses designed for cosmetic purposes. Furthermore, Interojo possesses technological competitiveness that enables it to independently design and mass-produce the full spectrum of soft contact lenses, including daily disposable and scheduled replacement lenses.

Researcher Sim emphasized, "With FDA certification and the expansion of global partners, Interojo is projected to achieve record-high results this year. At a price-to-earnings ratio (PER) of 7.3 times, the company's valuation is highly attractive, making it an opportune time to renew interest."

This content was produced with the assistance of AI translation services.